Moleculin Biotech Inc

NASDAQ:MBRX   11:26:01 AM EDT
1.77
0.00 (0.00%)
Products, Regulatory

Moleculin Concludes Phase 1B And Opens Recruitment In Phase 2 Clinical Trial Of Annamycin For Treatment Of Soft Tissue Sarcoma Lung Metastases

Published: 07/28/2022 12:43 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases.
Moleculin Biotech Inc - Company Determines Rp2d to Be 360 Mg/m(2) and Will Begin Phase 2 Recruitment.
Moleculin Biotech Inc - Preliminary Phase 1b Data Demonstrated Clinical Activity, Defined As Stable Disease Or Better.